Subgroup Analysis of the Occurrence of Secondary Endpoints. by Karl Ingard (22582091)

Subjects:

Study flow chart. by Karl Ingard (22582091)

Subjects:

Kaplan-Meier curve of the primary outcome. by Karl Ingard (22582091)

Subjects:

Number of Patients Who Reached the Primary and Secondary Endpoints During Follow-up. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Behaviour and significance of reservoir evaporation and seepage losses – an experience of four reservoirs in Damodar River Valley, India by Dipankar Chaudhuri (498103)

“…Annual seepage loss and its mean rate increased gradually for a considerable period during initial operation stage; later, both decreased and stabilized. …”

TNFAIP9 expression was increased in mice with chronic kidney disease (CKD) induced by 5/6 nephrectomy (Nx). by Ying Chen (9697)

SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

Subjects:

KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

Subjects:

Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

Subjects:

Changes in AL (A) and SE (B) according to the treatment time estimation curve in patients given 0.125% atropine. by Zi-Rong Chen (9227618)

Subjects:

Flow diagram of the patient selection into the final analysis. by Zi-Rong Chen (9227618)

Subjects:

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

Subjects:

Associations between demographic variables, In4_SED and SE changes at 6 and 12 months after 4_SED (<i><i>n</i></i> = 80). by Zi-Rong Chen (9227618)

Subjects:

Table 2 - Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study by Zi-Rong Chen (9227618)

Subjects:

Weights and body temperatures of bats assigned to the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

Subjects:

MARV shedding dynamics in bats from the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

Subjects:

Cumulative MARV shedding in bats from the SOSV-MARV and KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

Subjects:

MARV shedding dynamics in bats from the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

Subjects:

Subgroup Analysis of Sleep Duration and Cardiovascular Disease Risk in Type 2 Diabetes Patients. by Zhi Jin (3742471)

Subjects: